Company Description
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was...
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.
Valuation
Price to Sales Ratio
303.90
Price to Book Ratio
1.89
Enterprise Value to EBITDA
-3.83
Enterprise Value to Sales
399.06
Total Debt to Enterprise Value
0.20
Efficiency
Revenue/Employee
37,400.00
Income Per Employee
-2,729,900.00
Receivables Turnover
0.05
Total Asset Turnover
0.00
Liquidity
Current Ratio
5.92
Quick Ratio
5.92
Cash Ratio
4.78
Profitability
Operating Margin
-6,938.77
Pretax Margin
-7,299.20
Net Margin
-7,299.20
Return on Assets
-30.04
Return on Equity
-38.91
Return on Total Capital
-30.37
Return on Invested Capital
-32.95
Capital Structure
Total Debt to Total Equity
25.47
Total Debt to Total Capital
20.30
Total Debt to Total Assets
18.72
Long-Term Debt to Equity
17.01
Long-Term Debt to Total Capital
13.56
Officers and Executives
| Name | Age | Officer Since | Title |
|---|---|---|---|
| Dr. Raymond J. Tesi | 64 | 2015 | Chairman, President, Chief Executive Officer & CMO |
| Mr. David J. Moss | 49 | 2015 | Chief Financial Officer, Secretary & Treasurer |
| Ms. Tara Lehner | - | - | Vice President-Clinical Operations |
| Dr. Mark Lowdell | 57 | 2015 | Chief Scientific & Manufacturing Officer |
| Mr. Joshua S. Schoonover | - | - | Associate General Counsel |
Insider Actions
| 03/17/2023 |
David J. Moss CFO, Treasurer & Secretary |
2,500 | Acquisition at $6.42 per share. | 16,050 |
| 05/27/2022 |
David J. Moss CFO, Treasurer & Secretary |
3,000 | Acquisition at $6.79 per share. | 20,370 |
| 05/26/2022 |
Raymond J. Tesi President and CEO; Director |
6,300 | Acquisition at $6.41 per share. | 40,383 |
| 05/26/2022 |
David J. Moss CFO, Treasurer & Secretary |
7,700 | Acquisition at $6.27 per share. | 48,279 |
| 03/22/2022 |
Raymond J. Tesi President and CEO; Director |
23,724 | Award at $8.43 per share. | 199,993 |
| 03/22/2022 |
Mark Lowdell Chief Scientific Officer |
23,590 | Award at $8.43 per share. | 198,863 |
| 03/22/2022 |
David J. Moss CFO, Treasurer & Secretary |
17,793 | Award at $8.43 per share. | 149,994 |
| 03/22/2022 |
J. Kelly Ganjei Director |
17,793 | Award at $8.43 per share. | 149,994 |
| 11/17/2021 |
Scott Juda Director |
2,500 | Acquisition at $13.55 per share. | 33,875 |
| 11/03/2021 |
Raymond J. Tesi President and CEO; Director |
3,626 | Disposition at $20 per share. | 72,520 |
| 11/03/2021 |
Mark Lowdell Chief Scientific Officer |
701 | Disposition at $20 per share. | 14,020 |
| 11/03/2021 |
David J. Moss CFO, Treasurer & Secretary |
1,025 | Disposition at $20 per share. | 20,500 |
| 10/27/2021 |
Raymond J. Tesi President and CEO; Director |
6,517 | Disposition at $20 per share. | 130,340 |
| 10/27/2021 |
Mark Lowdell Chief Scientific Officer |
2,357 | Disposition at $20 per share. | 47,140 |
| 10/27/2021 |
David J. Moss CFO, Treasurer & Secretary |
2,079 | Disposition at $20 per share. | 41,580 |
| 10/25/2021 |
David J. Moss CFO, Treasurer & Secretary |
13 | Disposition at $20 per share. | 260 |
| 10/22/2021 |
Raymond J. Tesi President and CEO; Director |
23,616 | Disposition at $20 per share. | 472,320 |
| 10/22/2021 |
Mark Lowdell Chief Scientific Officer |
400 | Disposition at $20 per share. | 8,000 |
| 10/22/2021 |
David J. Moss CFO, Treasurer & Secretary |
1,142 | Disposition at $20 per share. | 22,840 |
| 09/03/2021 |
Xencor, Inc. |
108,000 | Derivative/Non-derivative trans. at $7.8 per share. | 842,400 |
MarketWatch News on INMB
-
INmune Bio downgraded to neutral from buy at B. Riley
- Tomi Kilgore
-
INmune Bio stock price target cut to $7 from $14 at B. Riley
- Tomi Kilgore
-
Robinhood investors are propping up this stock market, says JPMorgan
- Barbara Kollmeyer
-
Analyst Raises Price Targets on 3 Smaller Alzheimer's Stocks
- Barron's Online
-
INmune Bio stock price target raised to $42 from $32 at Maxim Group
- Tomi Kilgore
-
INmune Bio started at buy with $29 stock price target at B. Riley
- Tomi Kilgore
-
INmune Bio stock price target raised to $32 from $16 at Maxim Group
- Tomi Kilgore
-
INmune Bios started at buy with $13 stock price target at Maxim Group
- Tomi Kilgore
Other News on INMB
-
- Edgar Online - (EDG = 10Q, 10K)
-
- Edgar Online - (EDG = 10Q, 10K)
-
INmune Bio, Inc. (INMB) Q3 2022 Earnings Call Transcript
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
INmune Bio, Inc. (INMB) Q2 2022 Earnings Call Transcript
- Motley Fool
-
- Edgar Online - (EDG = 10Q, 10K)
